Table 1.
Clinicopathological characteristics of patients with ALK-rearranged NSCLC receiving ALK-TKIs.
| Variable | Total |
|---|---|
| Age | |
| Median (25%, 75%) | 51 (41, 61) |
| Sex, n (%) | |
| Male | 21 (40%) |
| Female | 31 (60%) |
| Smoking status, n (%) | |
| Non-smoker | 38 (73%) |
| Former/current smoker | 14 (27%) |
| Stage, n (%) | |
| IIIB–IIIC | 3 (6%) |
| IV | 49 (94%) |
| Histology, n (%) | |
| Adenocarcinoma | 52 (100%) |
| ECOG PS, n (%) | |
| 0 | 18 (35%) |
| 1 | 27 (52%) |
| 2 | 7 (13%) |
| Metastasis, n (%) | |
| Brain | 18 (35%) |
| Bone | 24 (46%) |
| Liver | 11 (21%) |
| Adrenal glands | 4 (8%) |
| Pleura | 13 (25%) |
| Contralateral lung | 18 (35%) |
| TKI, n (%) | |
| Crizotinib | 42 (81%) |
| Alectinib | 10 (19%) |
| PD-L1 TPS, n (%) | |
| 0% | 23 (44%) |
| 1–49% | 17 (33%) |
| ≥50% | 12 (23%) |
ECOG PS, Eastern Cooperative Oncology Group performance status; PD-L1, programmed cell death-ligand 1; TKI, tyrosine kinase inhibitor.